Literature DB >> 9437204

Lipoprotein heterogeneity and apolipoprotein B metabolism.

C J Packard1, J Shepherd.   

Abstract

The apolipoprotein B containing lipoproteins VLDL, IDL, and LDL exhibit variation in their structure, function, and metabolism. These major lipoprotein classes can be fractionated into apparently discrete components by density gradient centrifugation or affinity chromatography. Examination of the behavior of subfractions in vivo reveals the presence of metabolic channels within the VLDL-LDL delipidation cascade so that the pedigree of a lipoprotein in part determines its metabolic fate. Evidence from VLDL and LDL apoB turnovers together with epidemiological data allows the construction of a quantitative model for the generation of small, dense LDL. This lipoprotein subspecies is one component of the dyslipidemic syndrome known as the atherogenic lipoprotein phenotype, a common disorder in those at risk for coronary heart disease. Understanding lipoprotein heterogeneity is an essential step in the further discovery of the pathogenesis of atherosclerosis and in the tailoring of pharmacologic treatment for subjects at risk.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9437204     DOI: 10.1161/01.atv.17.12.3542

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  68 in total

Review 1.  The effect of n-3 fatty acids on low density lipoprotein subfractions.

Authors:  B A Griffin
Journal:  Lipids       Date:  2001       Impact factor: 1.880

Review 2.  The physiology of lipoproteins.

Authors:  Thomas N Tulenko; Anne E Sumner
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

Review 3.  The genetics of familial combined hyperlipidaemia.

Authors:  Martijn C G J Brouwers; Marleen M J van Greevenbroek; Coen D A Stehouwer; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Nat Rev Endocrinol       Date:  2012-02-14       Impact factor: 43.330

4.  Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study.

Authors:  Jean-Claude Ansquer; Christophe Corda; Karine Le Malicot; Valerie Jessent
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

Review 5.  Hepatic ABCA1 and VLDL triglyceride production.

Authors:  Mingxia Liu; Soonkyu Chung; Gregory S Shelness; John S Parks
Journal:  Biochim Biophys Acta       Date:  2011-10-06

Review 6.  Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.

Authors:  David E Cohen; Edward A Fisher
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

7.  Metabolic responses to prolonged consumption of glucose- and fructose-sweetened beverages are not associated with postprandial or 24-h glucose and insulin excursions.

Authors:  Kimber L Stanhope; Steven C Griffen; Andrew A Bremer; Roel G Vink; Ernst J Schaefer; Katsuyuki Nakajima; Jean-Marc Schwarz; Carine Beysen; Lars Berglund; Nancy L Keim; Peter J Havel
Journal:  Am J Clin Nutr       Date:  2011-05-25       Impact factor: 7.045

Review 8.  Sirtuins-Mediated System-Level Regulation of Mammalian Tissues at the Interface between Metabolism and Cell Cycle: A Systematic Review.

Authors:  Parcival Maissan; Eva J Mooij; Matteo Barberis
Journal:  Biology (Basel)       Date:  2021-03-04

Review 9.  Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.

Authors:  Chris J Packard
Journal:  Curr Cardiol Rep       Date:  2018-06-14       Impact factor: 2.931

Review 10.  Dynamics of hepatic and intestinal cholesterol and bile acid pathways: The impact of the animal model of estrogen deficiency and exercise training.

Authors:  Jean-Marc Lavoie
Journal:  World J Hepatol       Date:  2016-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.